Criteria for Use of Selected Drugs
|
The documents on this page include VHA Pharmacy Benefits Management (PBM) and Medical Advisory Panel (MAP) Criteria for Use documents. |
| Need information on Portable Document Format, PDF? All documents are in PDF format unless specified |
| Acamprosate, Criteria for Use |
| Adefovir, Criteria for Use |
| Agalsidase, Criteria for Non-Formulary Use |
| Alatrofloxacin/Trovafloxacin, Criteria for Non-Formulary Use |
| Alemtuzumab, Criteria For Non-Formulary Use |
|
Alpha-Adrenergic Blockers in the Management of Patients with HTN (ALLHAT) |
| Azacitidine, Criteria for Use |
|
Clinically Uroselective Alpha Blockers, Criteria for Non-Formulary Use |
| Combination Alpha-Blocker & Finasteride Therapy for BPH, Criteria for Use |
|
Angiotensin II Receptor Antagonists (AIIRAs), Criteria for Use |
Antiemetic, Criteria for Use |
Antiviral Agents for Influenza, Criteria For Use |
| Becaplermin, Criteria for Non-Formulary Use |
| Topical Anesthesia for Surfaces of the Nasopharynx, Oropharynx, Laryngotracheal Region and Airway, Criteria for Use |
|
Beta-Adrenergic Blockers, Criteria for Use |
| Biologics for Psoriasis, Criteria for Non-Formulary Use (Updated) |
| Buprenorphine Criteria for Use |
| Cholinesterase Inhibitor, Criteria for Use |
| Cilostazol, Criteria for Use |
| Cinacalcet, Criteria for Non-Formulary Use |
| Clopidogrel, Criteria for Use |
| Dihydropyridine Calcium Antagonists, Criteria for Use |
| Drotrecogin Alfa, Criteria for Use |
| Duloxetine, Criteria for Non-Formulary Use |
| Enfuvirtide, Criteria for Use |
| Enoxaparin, Criteria for Use in Mechanical Heart Valve Patients |
| Erlotinib, Criteria for Non-Formulary Use |
| Erythropoietin Criteria for Use for Hepatitis C, Criteria for Use | Eszopiclone, Criteria for Non-Formulary Use |
| Exenatide, Criteria for Non-Formulary Use |
| Ezetimibe Criteria for Non-Formulary Use |
| Fluoroquinolone ,Criteria for Use |
| Fluva-Prava-Atorva-Rosuv Criteria for Non-Formulary Use |
| Fondapariux, Criteria for Use |
| Gabapentin, Criteria for Use |
| Gefitinib Criteria for Non-Formulary Use |
| GCSF Criteria for Use for Hepatitis C, Criteria for Use |
| Fuzeon, Criteria for Use |
|
HMGs, Criteria for Non-Formulary Use in Patients Receiving Protease Inhibitor Therapy |
| Highly Teratogenic Retinoids and High-dose Vitamin A, Criteria for Use |
| Imatinib, Criteria for Use |
| Initiating Therapy In Early Parkinson’s Disease, Criteria for Use |
|
Insulin Glargine, Criteria for Non-formulary Use |
| Leflunomide and Biologic DMARDs for Rheumatoid Arthritis, Criteria for use |
| Leukotriene Inhibitor, Criteria for Use |
| Leuprolide Implantable (Viadur) Criteria for Non-Formulary Use |
| Levetiracetam, Criteria for Use |
|
Linezolid, Quinupristin-Dalfopristin, and Daptomycin, Criteria for Use |
| Memantine, Criteria for Use |
| Meperidine, Criteria for Use |
|
Multiple Sclerosis, Use of Disease Modulating Agents in MS |
|
Omacor, Criteria for Non-formulary Use |
| Omalizumab, Criteria for Non-Formulary Use |
| Orlistat - Criteria for Use |
|
Oxycodone CR, Criteria for use, Treatment Algorithm |
| Pantoprazole I.V. Criteria for Use Pantoprazole I.V. Literature Review |
| Pegaptanib, Criteria for Non-Formulary Use |
| Pegfilgrastim, Criteria for Non-Formulary Use |
| Pharmacologic Management of Primary Pulmonary Hypertension, Criteria for Use |
|
Pharmaceutical Selection of Antiplatelet Therapy in Cerebrovascular Disease, Criteria for Use |
| Phosphate Binder, Criteria for Non-Formulary Use |
| Pramlintide Criteria for Non-Formulary Use |
| Proton Pump Inhibitors, High-dose, Criteria for Use |
| Quinine Sulfate, Criteria for Non Formulary Use |
| Appendix I (Noctural Leg Cramps) |
| Ramipril, Criteria for Non Formulary Use |
| Risperidone Long-Acting, Criteria for Use |
| Sibutramine - Criteria for Use |
|
Synvisc and Hyalgan, Criteria for Non-Formulary Use |
| Tegaserod, Criteria for Non-Formulary Use |
| Teriparatide, Criteria for Non-Formulary Use |
| Tiotropium, Criteria for Non-Formulary Use |
| Tipranavir, - Criteria for Use |
|
TZD (Thiazolidinediones, Rosiglitazone, Pioglitazone) Criteria for Use |
| Ziprasidone IM Criteria for Non-Formulary Use |
|
Ziprasidone, Criteria for Use |